{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:40:07Z","timestamp":1784544007992,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Fred C. and Katherine B. Andersen Foundation","award":["5R01DK107870"],"award-info":[{"award-number":["5R01DK107870"]}]},{"name":"NIH","award":["DK125252"],"award-info":[{"award-number":["DK125252"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hyperphosphatemia confers adverse cardiovascular outcomes, and commonly occurs in late-stage CKD. Fibroblast growth factor 7 (FGF7) is a phosphaturic peptide which decreases renal phosphate transport <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Serum FGF7 concentrations are reduced in hyperphosphatemic patients with hypophosphatasia and are elevated in some hypophosphatemic patients with tumor-induced osteomalacia. No data, however, are available on whether circulating FGF7 concentrations increase to compensate for phosphate retention in CKD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a cross-sectional study performed among 85 adult patients with varying estimated glomerular filtration rates (eGFR). We measured serum intact FGF7 (iFGF7) concentration using an iFGF7 immunoassay and determined its associated factors. Relationships between eGFR and mineral metabolism biomarkers [phosphate, iFGF7, iFGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)<jats:sub>2<\/jats:sub>D)] were explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For eGFRs of \u2265\u200960 (<jats:italic>n<\/jats:italic>\u2009=\u200931), 45\u201359 (<jats:italic>n<\/jats:italic>\u2009=\u200916), 30\u201344 (<jats:italic>n<\/jats:italic>\u2009=\u200911), 15\u201329 (<jats:italic>n<\/jats:italic>\u2009=\u200915), and &lt;\u200915 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> (<jats:italic>n<\/jats:italic>\u2009=\u200912), median (IQ25-75) iFGF7 concentrations were 46.1 (39.2\u201356.9), 43.1 (39.0-51.5), 47.3 (38.3\u201366.5), 47.7 (37.7\u201355.8), and 49.6 (42.5\u201365.6) pg\/mL, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.62). Significant increases in serum iFGF23, PTH, and phosphate were observed at eGFRs of &lt;\u200933 (95\u2009% CI, 26.40-40.05), &lt;\u200929 (95\u2009% CI, 22.51\u201335.36), and &lt;\u200922 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> (95\u2009% CI, 19.25\u201325.51), respectively, while significant decreases in serum 1,25(OH)<jats:sub>2<\/jats:sub>D were observed at an eGFR of &lt;\u200952 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> (95\u2009% CI, 42.57\u201361.43). No significant correlation was found between serum iFGF7 and phosphate, iFGF23, PTH or 1,25(OH)<jats:sub>2<\/jats:sub>D. In multivariable analyses, body mass index (per 5\u00a0kg\/m<jats:sup>2<\/jats:sup> increase) was independently associated with the highest quartile of serum iFGF7 concentration (OR, 1.20; 95\u2009% CI, 1.12\u20131.55).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compensatory decreases in circulating 1,25(OH)<jats:sub>2<\/jats:sub>D and increases in circulating iFGF23 and PTH, but not iFGF7, facilitate normalization of serum phosphate concentration in early stages of CKD. Whether other circulating phosphaturic peptides change in response to phosphate retention in CKD patients deserves further study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02311-3","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T14:02:59Z","timestamp":1617112979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)2D and normal FGF7 concentrations characterize patients with CKD"],"prefix":"10.1186","volume":"22","author":[{"given":"Kittrawee","family":"Kritmetapak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Losbanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor E.","family":"Berent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Ashrafzadeh-Kian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Algeciras-Schimnich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolaine M.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder J.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"2311_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","volume":"6","author":"A Covic","year":"2018","unstructured":"Covic A, Vervloet M, Massy ZA, Torres PU, Goldsmith D, Brandenburg V, et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol. 2018;6:319\u201331.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2311_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/ckj\/sfz187","volume":"13","author":"J Bover","year":"2020","unstructured":"Bover J, Ure\u00f1a-Torres P, Mateu S, DaSilva I, Gr\u00e0cia S, S\u00e1nchez-Baya M, et al. Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? Clin Kidney J. 2020;13:513\u201321.","journal-title":"Clin Kidney J"},{"key":"2311_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters. Kidney Int. 2017;92:26\u201336.","journal-title":"Kidney Int"},{"key":"2311_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"2311_CR5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370\u20138.","journal-title":"Kidney Int"},{"key":"2311_CR6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1210\/jc.2004-0357","volume":"90","author":"TO Carpenter","year":"2005","unstructured":"Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab. 2005;90:1012\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"2311_CR7","doi-asserted-by":"crossref","unstructured":"Beer HD, Gassmann MG, Munz B, Steiling H, Engelhardt F, Bleuel K, et al. Expression and function of keratinocyte growth factor and activin in skin morphogenesis and cutaneous wound repair. J Investig Dermatol Symp Proc. 2000;5:34\u20139.","DOI":"10.1046\/j.1087-0024.2000.00009.x"},{"key":"2311_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/019262339902700113","volume":"27","author":"DM Danilenko","year":"1999","unstructured":"Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol. 1999;27:64\u201371.","journal-title":"Toxicol Pathol"},{"key":"2311_CR9","first-page":"547","volume":"126","author":"J Qiao","year":"1999","unstructured":"Qiao J, Uzzo R, Obara-Ishihara T, Degenstein L, Fuchs E, Herzlinger D. FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Dev Camb Engl. 1999;126:547\u201354.","journal-title":"Dev Camb Engl"},{"key":"2311_CR10","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00198-018-4618-2","volume":"29","author":"G Marcucci","year":"2018","unstructured":"Marcucci G, Masi L, Ferrar\u00ec S, Haffner D, Javaid MK, Kamenick\u00fd P, et al. Phosphate wasting disorders in adults. Osteoporos Int. 2018;29:2369\u201387.","journal-title":"Osteoporos Int"},{"key":"2311_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5414\/CN108596","volume":"85","author":"S Bansal","year":"2016","unstructured":"Bansal S, Khazim K, Suri R, Martin D, Werner S, Fanti P. Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23. Clin Nephrol. 2016;85:57\u201362.","journal-title":"Clin Nephrol"},{"key":"2311_CR12","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.bone.2020.115300","volume":"134","author":"MP Whyte","year":"2020","unstructured":"Whyte MP, Zhang F, Wenkert D, Mumm S, Berndt TJ, Kumar R. Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia. Bone. 2020;134:115300.","journal-title":"Bone"},{"key":"2311_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/aje\/148.7.631","volume":"148","author":"R Pastor","year":"1998","unstructured":"Pastor R, Guallar E. Use of two-segmented logistic regression to estimate change-points in epidemiologic studies. Am J Epidemiol. 1998;148:631\u201342.","journal-title":"Am J Epidemiol"},{"key":"2311_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/oxfordjournals.aje.a115101","volume":"129","author":"RM Mickey","year":"1989","unstructured":"Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125\u201337.","journal-title":"Am J Epidemiol"},{"key":"2311_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0065-230X(04)91003-2","volume":"91","author":"PW Finch","year":"2004","unstructured":"Finch PW, Rubin JS. Keratinocyte growth factor\/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res. 2004;91:69\u2013136.","journal-title":"Adv Cancer Res"},{"key":"2311_CR16","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1101\/gad.990702","volume":"16","author":"DM Ornitz","year":"2002","unstructured":"Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002;16:1446\u201365.","journal-title":"Genes Dev"},{"key":"2311_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djj228","volume":"98","author":"PW Finch","year":"2006","unstructured":"Finch PW, Rubin JS. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst. 2006;98:812\u201324.","journal-title":"J Natl Cancer Inst"},{"key":"2311_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1359-6101(98)00010-0","volume":"9","author":"S Werner","year":"1998","unstructured":"Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev. 1998;9:153\u201365.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2311_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.jid.5700786","volume":"127","author":"S Werner","year":"2007","unstructured":"Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol. 2007;127:998\u20131008.","journal-title":"J Invest Dermatol"},{"key":"2311_CR20","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1093\/ndt\/gfi040","volume":"20","author":"C Mei","year":"2005","unstructured":"Mei C, Mao Z, Shen X, Wang W, Dai B, Tang B, et al. Role of keratinocyte growth factor in the pathogenesis of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2005;20:2368\u201375.","journal-title":"Nephrol Dial Transplant"},{"key":"2311_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1681\/ASN.2014121253","volume":"27","author":"AJ van Ballegooijen","year":"2016","unstructured":"van Ballegooijen AJ, Rhee EP, Elmariah S, de Boer IH, Kestenbaum B. Renal Clearance of Mineral Metabolism Biomarkers. J Am Soc Nephrol. 2016;27:392\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"2311_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31\u20138.","journal-title":"Kidney Int."},{"key":"2311_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ki.1992.22","volume":"41","author":"KG Koenig","year":"1992","unstructured":"Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int. 1992;41:161\u20135.","journal-title":"Kidney Int"},{"key":"2311_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429\u201335.","journal-title":"J Bone Miner Res"},{"key":"2311_CR25","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"2311_CR26","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1074\/jbc.M207872200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278:2206\u201311.","journal-title":"J Biol Chem"},{"key":"2311_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1126\/science.1188357","volume":"190","author":"MR Hughes","year":"1975","unstructured":"Hughes MR, Brumbaugh PF, Hussler MR, Wergedal JE, Baylink DJ. Regulation of serum 1alpha,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975;190:578\u201380.","journal-title":"Science"},{"key":"2311_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/0003-9861(73)90010-6","volume":"154","author":"Y Tanaka","year":"1973","unstructured":"Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys. 1973;154:566\u201374.","journal-title":"Arch Biochem Biophys"},{"key":"2311_CR29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/sj.ki.5002532","volume":"72","author":"M Usatii","year":"2007","unstructured":"Usatii M, Rousseau L, Demers C, Petit J-L, Brossard J-H, Gascon-Barr\u00e9 M, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int. 2007;72:1330\u20135.","journal-title":"Kidney Int"},{"key":"2311_CR30","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1046\/j.1523-1755.1999.0550031019.x","volume":"55","author":"E Ishimura","year":"1999","unstructured":"Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55:1019\u201327.","journal-title":"Kidney Int"},{"key":"2311_CR31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","volume":"45","author":"RE LaClair","year":"2005","unstructured":"LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026\u201333.","journal-title":"Am J Kidney Dis"},{"key":"2311_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ki.1996.283","volume":"50","author":"M Denda","year":"1996","unstructured":"Denda M, Finch J, Brown AJ, Nishii Y, Kubodera N, Slatopolsky E. 1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int. 1996;50:34\u20139.","journal-title":"Kidney Int"},{"key":"2311_CR33","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1073\/pnas.72.12.4871","volume":"72","author":"PF Brumbaugh","year":"1975","unstructured":"Brumbaugh PF, Hughes MR, Haussler MR. Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci U S A. 1975;72:4871\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2311_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2215\/CJN.03050608","volume":"4","author":"P Muntner","year":"2009","unstructured":"Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2009;4:186\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2311_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.ki.5001606","volume":"70","author":"J-C Souberbielle","year":"2006","unstructured":"Souberbielle J-C, Boutten A, Carlier M-C, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345\u201350.","journal-title":"Kidney Int"},{"key":"2311_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ajkd.2019.07.022","volume":"75","author":"T Isakova","year":"2020","unstructured":"Isakova T, Cai X, Lee J, Mehta R, Zhang X, Yang W, et al. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2020;75:235\u201344.","journal-title":"Am J Kidney Dis"},{"key":"2311_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010;95:578\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"2311_CR38","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/ndt\/gfu063","volume":"29","author":"J Chudek","year":"2014","unstructured":"Chudek J, Koce\u0142ak P, Owczarek A, Bo\u017centowicz-Wikarek M, Mossakowska M, Olszanecka-Glinianowicz M, et al. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly. Nephrol Dial Transplant. 2014;29:1757\u201363.","journal-title":"Nephrol Dial Transplant"},{"key":"2311_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1159\/000443452","volume":"41","author":"M Bo\u017centowicz-Wikarek","year":"2016","unstructured":"Bo\u017centowicz-Wikarek M, Owczarek A, Koce\u0142ak P, Olszanecka-Glinianowicz M, Wi\u0119cek A, Chudek J. C-Terminal to Intact Fibroblast Growth Factor 23 Ratio in Relation to Estimated Glomerular Filtration Rate in Elderly Population. Kidney Blood Press Res. 2016;41:519\u201326.","journal-title":"Kidney Blood Press Res"},{"key":"2311_CR40","doi-asserted-by":"publisher","first-page":"p23-32","DOI":"10.1159\/000093277","volume":"104","author":"S Pande","year":"2006","unstructured":"Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104:p23-32.","journal-title":"Nephron Physiol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02311-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T14:05:30Z","timestamp":1617113130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02311-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02311-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Mayo Clinic Institutional Review Board (IRB reference number 19-010395).The study was reviewed by the Mayo Clinic IRB Ethics Committee and is determined to be exempt from the requirement for the informed consent in accordance with applicable HIPAA regulations (45 CFR 46.116d, category 1). This study was performed in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}